Marcellino Rau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcellino Rau has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aizhang Xu
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10021, USA
1 shared publication - Haijun Zhang
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10021, USA
1 shared publication - Sama Ayoub
Weill Cornell Medicine-Qatar, Doha 24144, Qatar
1 shared publication - Xiaojing Ma
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10021, USA
1 shared publication - Yuhang Wu
Middlebury College, Middlebury, VT 05753, USA
1 shared publication
Latest Publications
- Open Access
Regulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy
Regulatory T cells (Tregs) are a specialized subset of CD4+ T lymphocytes essential for maintaining immune tolerance and preventing autoimmunity. However, in breast cancer, tumors exploit Tregs to establish an immunosuppressive microenvironment that enables immune evasion, accelerates progression, and contributes to therapeutic resistance. This review synthesizes current evidence on the role of Tregs in invasive breast cancer (IBC), highlighting their prognostic significance across molecular subtypes, mechanisms of immune suppression, and impact on treatment response. We integrated mechanistic and clinical insights to discuss opportunities for Treg-targeted therapeutic strategies, with attention paid to challenges such as autoimmunity, compensatory resistance, and subtype-specific heterogeneity. Finally, we outline future directions, including biomarker-driven precision medicine, novel therapeutic combinations, advanced preclinical models, as well as potential artificial intelligence-assisted approaches that aim to selectively disrupt tumor-promoting Treg functions while preserving the systemic immune balance.
Open AccessRegulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy
Regulatory T cells (Tregs) are a specialized subset of CD4+ T lymphocytes essential for maintaining immune tolerance and preventing autoimmunity. However, in breast cancer, tumors exploit Tregs to establish an immunosuppressive microenvironment that enables immune evasion, accelerates progression, and contributes to therapeutic resistance. This review synthesizes current evidence on the role of Tregs in invasive breast cancer (IBC), highlighting their prognostic significance across molecular subtypes, mechanisms of immune suppression, and impact on treatment response. We integrated mechanistic and clinical insights to discuss opportunities for Treg-targeted therapeutic strategies, with attention paid to challenges such as autoimmunity, compensatory resistance, and subtype-specific heterogeneity. Finally, we outline future directions, including biomarker-driven precision medicine, novel therapeutic combinations, advanced preclinical models, as well as potential artificial intelligence-assisted approaches that aim to selectively disrupt tumor-promoting Treg functions while preserving the systemic immune balance.